Short interest for Viatris gives investors a sense of the degree to which investors are betting on the decline of Viatris's stock. Short interest data is updated every two weeks.

Viatris Stock (NASDAQ:VTRS), Short Interest Report

Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

VTRS

Biotech

Earnings

News

Guidance

Health Care

Movers

General

Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.

Weak Sales From Lipitor, Norvasc Hurt Viatris&#39; Q1 Earnings, Lowers Annual Forecast

Bull and bear stock market index

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Large Cap

Market Summary

Bonds

Commodities

Currency ETFs

Forex

Intraday Update

Markets

Tech

ETFs

$BTC

ABNB

AKAM

BLNK

SPDR Dow Jones Industrial Average ETF Trust

DUOL

EQIX

EXAS

HOOD

MARA

NVTS

RBLX

SYNA

USFD

PowerShares DB US Dollar Index Bullish Fund

XLRE

Select Sector SPDR-Consumer Discretionary

YELP

Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve interest rate cuts.

Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What&#39;s Driving Markets Thursday?

nyse ai

Analyst Color

Macro Economic Events

Mid Cap

REIT

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Small Cap

Economics

Federal Reserve

Analyst Ratings

Real Estate

AXON

BABA

BIDU

DLTR

EBAY

FSLR

MNST

OKTA

PARA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SNOW

NTXT

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last quarter of the year.

Stocks Fall Ahead Of Fed&#39;s Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What&#39;s Driving Markets Wednesday?

Viatris Inc

Ampco-Pittsburgh Q1 2024 EPS $(0.14) Down From $0.03 YoY, Sales $110.2M Up From $104.8M YoY

Oppenheimer analyst Brian Schwartz maintains Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Outperform and raises the price target from $95 to $100.

Price Target

AGYS

Oppenheimer Maintains Outperform on Agilysys, Raises Price Target to $100

Jefferies analyst Eun Yang assumes Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy rating and raises Price Target to $8.

Initiation

TSHA

Jefferies Assumes Taysha Gene Therapies at Buy, Raises Price Target to $8

BranchOut Food  Signs Lease For Production Facility In Peru; Estimates Facility Has $40M In Production Capacity, Estimated 40-50% Gross Margins

Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 10.53 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $148.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 196.00 percent. This is a 123.70 percent increase over sales of $66.16 thousand the same period last year.

OVID

Ovid Therapeutics Q1 EPS $(0.17) Beats $(0.21) Estimate, Sales $148.00K Beat $50.00K Estimate

On Friday May 10th, Live on Benzinga TV, Sandra Stone with Trading Made Simple LLC and Zunaid Soleman were discussing potential trade ideas. &nbsp;
<h3>Trade 1: Breakout On Microsoft Corp.</h3>
<ul>
<li>Reason: The price of $MSFT (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) stock reaching a key level at 415.00, a break above this level of resistance on the chart, indicating a potential bullish trend and an opportunity for price appreciation. We took a May 17th CALL DEBIT SPREAD 415 CALL/417.50 CALL for .92. A risk defined trade.</li>
<li>Profit Possibilities: If the breakout is genuine, the stock price could continue to rise, offering limited max profit of 1.58.</li>
<li>Risk Involved: Breakouts can be false signals, and the price could fall back below the support resistance level of 415.00. A stop-loss order for 25% below the breakout point can help limit potential losses.&nbsp;Total risk on the trade is .92.&nbsp;</li>
<li>Results:&nbsp; On Monday May 13, $MSFT gapped up over the weekend and opened +60% PROFIT.&nbsp; Taking profit when you have it is a key rule to trading. At the end of the day the remaining contracts were +5% PROFIT.&nbsp;The stock reached $419.00 before falling back to 413.72</li>
</ul>
<img alt="" src="https://www.benzinga.com/files/u1289625/msft.png" style="height:210px; width:624px" />
<h3>Trade 2: Earnings Event Alibaba</h3>
<ul>
<li>Reason: $BABA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>) was about to report its quarterly earnings. Depending on expectations, the stock price could react significantly to the news.&nbsp;A review of the last earnings report showed a significant rise before the earnings event.&nbsp;We took a May 17th 80/81 CALL DEBIT SPREAD for .39.&nbsp; This is a risk defined trade.&nbsp;</li>
<li>Profit Possibilities: The price could surge before and after earnings offering potential profits up to .61.</li>
<li>Risk Involved: Earnings reports can be unpredictable, and the stock price might not react as anticipated. Volatility leading up to and after the event can also be high. Total risk on the trade was .39 per contract.</li>
<li>Results: On Monday May 13th, $BABA rose to $84.60 and the CALL DEBIT SPREAD gained 130% Profit.&nbsp; Taking profits and leaving a runner for the earnings event is a popular strategy.<img alt="" src="https://www.benzinga.com/files/u1289625/baba.png" style="height:210px; width:624px" /></li>
</ul>
Disclaimer: Past performance does not guarantee future returns.&nbsp; Trading involves risk. This is not financial advice. Always do your own research before making any investment decisions. Consider your risk tolerance and only invest what you can afford to lose.
Sandra is live on Benzinga Fridays at 11:30am EST.&nbsp; She can be reached at <a href="https://trading">https://trading</a><a href="http://madesimple.org">madesimple.org</a>, X: <a href="https://twitter.com/Options_Sandy">Options_Sandy </a>and 714-202-7361 each trading day.&nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Trading Ideas

MSFT

Alibaba & Microsoft Unlocking Profits: How Options Trading Can Capitalize On Earnings & Breakouts

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11983630" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11983630">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11983630</a>

TSLA

Tesla Granted U.S. Patent #11983630:	Neural Networks For Embedded Devices

WIIM

NOTV

Inotive shares are trading lower after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $11.5 to $3.75.

LIFE

aTyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications

Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(0.69) by 263.77 percent. This is a 617.14 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $2.50 million by 58.84 percent. This is a 56.47 percent decrease over sales of $2.36 million the same period last year.

IMNM

Immunome Q1 EPS $(2.51) Misses $(0.69) Estimate, Sales $1.03M Miss $2.50M Estimate

Jim Cramer, the host of CNBC&#8217;s &#8220;Mad Money,&#8221; recently cautioned investors against buying MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock for exposure to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: During the lightning round segment of his show, Cramer advised, &#8220;If you want bitcoin, don't buy MicroStrategy. Buy bitcoin,&#8221; <a href="https://www.cnbc.com/2024/05/13/cramers-lightning-round-dont-buy-microstrategy.html">CNBC</a> reported on Tuesday.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38779727/trumps-crypto-pivot-is-bullish-but-for-whom-mad-crypto-money-with-ivan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Crypto Pivot Is Bullish&#8230;But For Whom? Mad Crypto Money With Ivan</a>
MicroStrategy, led by CEO Michael Saylor, is renowned as the largest corporate holder of Bitcoin. The company has been making significant strides in blockchain innovation, including the recent <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38594312/microstrategy-unveils-decentralized-identity-service-built-on-bitcoins-ordinals-protocol">launch of a decentralized identity service </a>called &#8220;MicroStrategy Orange,&#8221; which utilizes Bitcoin&#8217;s Ordinals inscriptions to offer trustless, tamper-proof, and long-lived decentralized identities.
Why It Matters: The advice from Cramer comes at a time when the cryptocurrency market is experiencing significant movements. On Monday, the top cryptocurrencies, including Bitcoin, <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38806160/bitcoin-ethereum-dogecoin-edge-higher-on-spot-etf-holdings-disclosure-and-roaring-kitty-fr">surged following the disclosure of investments</a> in spot Bitcoin ETFs by major banks such as Wells Fargo and JPMorgan Chase. This disclosure acted as a major trigger, propelling Bitcoin above $63,000.
Additionally, prominent investor Anthony Scaramucci predicted that Bitcoin, which currently makes up more than 30% of SkyBridge Capital&#8217;s assets,<a href="https://www.benzinga.com/top-stories/24/05/38796324/bitcoin-to-150-000-former-trump-ally-skybridge-founder-anthony-scaramucci-predicts-top-crypto-will-m"> will eventually reach $150,000 per coin</a>. He attributed his bullish stance to the recent ETF adoptions from BlackRock Inc. and other large financial firms.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, after closing 5.55% higher at $1,245.96 on Monday, MicroStrategy was trading 1.88% lower at $1,222.48 on Tuesday pre-market at the time of writing. Meanwhile, BTC was trading at 1.44% lower at $62,006.75 on Tuesday at the time of writing.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38788906/pepe-pumps-8-and-millionaire-trader-thinks-will-become-so-nutty-soon-that-his-1m-investmen?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Pepe Pumps 8% And Millionaire Trader Thinks Will Become &#8216;So Nutty Soon&#8217; That His $1M Investment Will Outperform All Others</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

MSTR

Jim Cramer's BTC Advice: 'If You Want Bitcoin, Don't Buy MicroStrategy'

SYRA

Syra Health shares are trading higher after the company that it is a subcontracts for LUKE on a 10-year $43 billion Defense Health Agency contract.

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is deploying advertisements to get its<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38774504/tesla-analyst-sees-annual-shareholder-meeting-as-key-to-determining-elon-musk-led-c"> shareholders to vote again</a> for CEO Elon Musk&#8216;s rescinded pay package from 2018.
What Happened: In a filing with the SEC, Tesla showcased the different ads and information the company has put out to inform its shareholders of the upcoming shareholder meeting and the two key votes about Musk&#8217;s pay package and the other on shifting Tesla&#8217;s state of incorporate from Delaware to Texas.
Musk&#8217;s 2018 pay package was rescinded by a Delaware court earlier this year terming it an &#8220;enormous&#8221; sum. The package was worth $55 billion at the time of issue.
Tesla is now trying to get the shareholders to vote again on the package at the upcoming shareholder meeting which will be held on June 13, 2024, at 3:30 p.m. Central Time (CT). The company is employing both Google ads and X ads to promote the upcoming vote.
Why It Matters: The EV giant has long been wary of advertising despite a push from shareholders. Last month, it was reported that the company laid off its marketing team in the U.S. after he deemed the ads made by the team as &#8220;too generic.&#8221;
Musk first expressed&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32439283/tesla-bulls-cheer-elon-musks-decision-to-try-some-advertising-it-could-be-amazingly" target="_blank" rel="noreferrer noopener">willingness to try traditional advertising</a>&nbsp;less than a year ago in May 2023. Until then, the company&nbsp;boasted of spending almost&nbsp;no money on advertising but&nbsp;became popular purely&nbsp;via word of mouth.
Since then, Tesla has attempted advertising on different platforms including&nbsp;YouTube,&nbsp;X, and even Meta Platforms'&nbsp;Instagram, and&nbsp;Facebook&nbsp;<a href="https://www.benzinga.com/news/24/03/37908129/facebook-isnt-lame-for-musk-anymore-tesla-rejoins-zuckerbergs-social-media-platform-after-ghosting-i" target="_blank" rel="noreferrer noopener">despite Musk's past criticism of them</a>.
However, in January, Tesla executives clarified during the fourth-quarter earnings call that while the lack of awareness impacted EV adoption, the company would not spend too much on advertising and marketing but instead spend it in areas and geographies where the company has low market share such as Japan.
Investor Reacts: Ross Gerber, the president and CEO of Gerber Kawasaki Wealth and Investment Management and a Tesla investor, criticized the company&#8217;s commitment to promoting the shareholder vote for the CEO&#8217;s pay while it refuses to scale up advertising for its products.
&#8220;They literally cut prices every week to sell cars and don't advertise their weekly sales. But they advertise for Elons pay,&#8221; Gerber wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">They literally cut prices every week to sell cars and don't advertise their weekly sales. But they advertise for Elons pay. <a href="https://twitter.com/search?q=%24tsla&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$tsla</a> <a href="https://t.co/UxnohcNDvS">https://t.co/UxnohcNDvS</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1790159728930406499?ref_src=twsrc%5Etfw">May 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/news/24/05/38782522/spacex-starship-likely-to-fly-for-4th-time-next-month-as-elon-musk-reaffirms-new-goals" target="_blank" rel="noreferrer noopener">SpaceX Starship Likely To Fly For 4th Time Next Month As Elon Musk Reaffirms New Goals</a>
Image made via photos on Shutterstock

Management

Tesla Spends On Musk's Pay Vote Ads, But Ross Gerber Feels EV Giant Could Advertise Weekly Sales Instead

Jefferies analyst David Windley downgrades Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) from Buy to Hold and lowers the price target from $11.5 to $3.75.

Downgrades

Jefferies Downgrades Inotiv to Hold, Lowers Price Target to $3.75

Releases Open Letter to AGS Stockholders Outlining Intention to Vote AGAINST Inadequate Proposal
NEW YORK, May 14, 2024 /PRNewswire/ --&nbsp;Emmett Investment Management LP (&quot;Emmett&quot;), an investment manager focused on small and mid-cap equities across developed markets and owner of approximately 1.5% of the outstanding stock of PlayAGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>)(&quot;AGS&quot; or the &quot;Company&quot;), today released an open letter to AGS stockholders outlining its intention to vote AGAINST the Company&#39;s inadequate proposed take-private transaction with Brightstar Capital Partners, which it believes significantly undervalues the Company.&nbsp;

Emmett Investment Management Opposes PlayAGS's Proposed Take-Private Transaction With Brightstar Capital Partners; Releases Open Letter To AGS Stockholders Outlining Intention To Vote Against Proposal

ESPR

Esperion Receives Five Year Patent Extension For Bempedoic Acid

RBC Capital analyst Anthony Codling initiates coverage on CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) with a Outperform rating and announces Price Target of $110.

RBC Capital Initiates Coverage On CRH with Outperform Rating, Announces Price Target of $110

Sony Group Corp&nbsp;(NYSE:&nbsp;SONY) reported fiscal fourth-quarter 2023 sales&nbsp;<a target="_blank" href="https://www.sony.com/en/SonyInfo/IR/library/presen/er/" rel="noreferrer noopener">growth&nbsp;</a>of 14% year-on-year to $23.49 billion (3.48 trillion Japanese yen), beating the analyst consensus estimate of&nbsp;$19.20 billion.&nbsp;
EPS of $1.04 (153.60 yen) beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $0.79</a>. The&nbsp;stock price climbed after the print.
Segments &amp; Profits:&nbsp;Game &amp; Network Services (G&amp;NS) revenue increased 2.2%&nbsp;Y/Y&nbsp;to ¥1.1 trillion, and operating income climbed 172.5%&nbsp;Y/Y&nbsp;to&nbsp;¥106 billion.
Music revenue rose 23%&nbsp;Y/Y&nbsp;to ¥429.9 billion, and operating income increased by 17.9%&nbsp;Y/Y&nbsp;to ¥71.2 billion. Pictures revenue increased by 13.3%&nbsp;Y/Y&nbsp;to ¥406.7 billion, and operating income improved by 98%&nbsp;Y/Y&nbsp;to ¥30.7 billion.
Entertainment, Technology &amp; Services (ET&amp;S) revenue grew by 7.9% Y/Y to ¥532.7 billion, and operating income loss was ¥(6.4) billion versus ¥(33.0) billion Y/Y.&nbsp;
Imaging &amp; Sensing Solutions revenue (I&amp;SS)&nbsp;increased by 14.2%&nbsp;Y/Y&nbsp;to ¥398.5 billion, and operating income climbed by 9.5%&nbsp;Y/Y&nbsp;to ¥34.7 billion.
Financial Services revenue improved from ¥470.6 billion to ¥672.9 billion, and operating income decreased by 49.6% Y/Y to ¥26.1 billion. Consolidated operating income rose by 57% Y/Y to ¥229.4 billion.&nbsp;
Sony sold 4.5 million PS5 units in the quarter&nbsp;versus&nbsp;6.3 million a year ago.&nbsp;Sony has indicated a slowdown in PlayStation 5 hardware sales and does not plan to release&nbsp;major&nbsp;titles from its leading franchises within the fiscal year, Bloomberg&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-05-14/sony-profit-outlook-misses-estimates-as-playstation-appeal-wanes?srnd=technology-vp&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.&nbsp;
It held ¥2.31 trillion in cash and equivalents as of March 31, 2024.
Buyback and Stock Split:&nbsp;Sony said it will buy back up to 2.46% of its shares for ¥250 billion and&nbsp;will&nbsp;implement a five-for-one stock split effective October 1.
Outlook:&nbsp;Sony expects fiscal 2024 sales of $84.9 billion ( ¥12.31 trillion) versus&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$80.93 billion consensus</a>.&nbsp;
The company anticipates growth in the current fiscal year, driven by its music publishing and smartphone image sensor units,&nbsp;benefiting&nbsp;from the weaker yen.&nbsp;Streaming services, including content from Lil Nas X and Michael&nbsp;Jackson&nbsp;bolster Sony&#8217;s music revenues, the report added.&nbsp;
Additionally, the smartphone market&#8217;s growth, particularly in China, has prompted increased investment in new hardware and components.
Sony expects PS5 sales for this fiscal year to be&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">approximately 18 million units.</a>
Sony&#8217;s shares have faced pressure due to concerns over its potential $26 billion bid for&nbsp;Paramount Global&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), raising investor concerns about the cost and integration challenges.
Price Action: SONY shares traded higher by 3.28% at $78.65 premarket at the last check Tuesday.
Image Source &#8211; Shutterstock

Equities

Buybacks

Stock Split

Media

PARAA

Sony Group Corporation American Depositary Shares

SONY

Sony Surpasses Expectations with Strong Q4 Sales, Plans Stock Split And Stock Buyback

Clearwater Will Aggregate Multi-Asset Client Investment Data, Help Increase Asset Flows and Strengthen Client Service
BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ -- <a href="https://www.clearwateranalytics.com/">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients. Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.

CWAN

Clearwater Analytics Selected By Erste Asset Management To Help Support Business Growth

Jefferies analyst Kaumil Gajrawala upgrades Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) from Hold to Buy and raises the price target from $335 to $360.

Upgrades

Jefferies Upgrades Boston Beer Co to Buy, Raises Price Target to $360

Viatris Inc. 2024 Q1 - Results - Earnings Call Presentation

Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Viatris (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtrs-stock-quote/">VTRS</a>) just reported results for the first quarter of 2024.<ul><li>Viatris reported earnings per share of 67 cents. This met the analyst estimate for EPS of 67 cents.</li><li>The company reported revenue of $3.66 billion.</li><li>This was 1% worse than the analyst estimate for revenue of $3.70 billion.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/vtrs-stock-earnings-viatris-for-q1-of-2024/">VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024

Viatris declares $0.12 dividend

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Health Catalyst (HCAT – Research Report), Bluebird Bio (BLUE – Re...

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)

About 70% of S&P 500 names beat EPS, while 47% soar past revenue estimates this week - Earnings Scorecard

Organon Graduates From Spinoff Skepticism, With A Yield Above 5%

8 out of 12 S&P 500 healthcare companies beat profit consensus this week: Earnings Scorecard

The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY), to diversify their portfolio. These stocks are top-rated in our proprietary rating system. Read on... The pharma industry's growth prospects look promising thanks to favorable government initiatives, rising healthcare expenditures, the growing need for quality healthcare and personalized treatments, and the rise in lifestyle-related diseases.
Amid this backdrop, investors could consider diversifying their portfolios by buying fundamentally strong pharma stocks such as Elanco Animal Health Incorporated (<a href="https://stocknews.com/stock/ELAN/">ELAN</a>), Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>), and Astellas Pharma Inc. (<a href="https://stocknews.com/stock/ALPMY/">ALPMY</a>). These stocks are top-rated in our proprietary <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> system.
Investors closely track the pharmaceutical industry due to its constant innovations and improvements, which enable people to live healthier and longer lives. According to Statista, worldwide pharmaceutical revenues are expected to grow at a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">CAGR of 6.2%</a> to reach $1.47 trillion by 2028.
The rise of chronic diseases such as cancer, arthritis, asthma, COPD, etc., and growth in the elderly population is boosting healthcare spending. Pharmaceutical companies are looking to manage and treat these diseases effectively. The U.S. pharmaceutical market is expected to <a href="https://www.grandviewresearch.com/industry-analysis/us-pharmaceuticals-market-report">grow at a 5.5% CAGR</a>, reaching $760 million by 2030.
Additionally, rising investments in R&amp;D and manufacturing facilities and incorporating digital technologies like artificial intelligence (AI), the Internet of Things, and big data analytics have bolstered the pharma industry by optimizing manufacturing processing and enhancing quality.
AI applications can create between <a href="https://www.scilife.io/blog/ai-pharma-innovation-challenges">$350 billion and $410 billion</a> in annual value for pharmaceutical companies by 2025. Meanwhile, the global animal health market is expected to grow due to rising pet populations, the requirement for productivity improvement in existing herds, and the emergence of new animal diseases.
The global animal health market's revenue is predicted to reach $112.30 billion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/animal-health-market">CAGR of 9%</a>.
Considering these factors, let's examine the fundamentals of the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> stock picks, beginning with the third choice.
Stock #3: Elanco Animal Health Incorporated (<a href="https://stocknews.com/stock/ELAN/">ELAN</a>)
ELAN innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products, that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands.
ELAN's trailing-12-month EBIT margin of 5.61% is 321.7% higher than the industry average of 1.33%. Likewise, its trailing-12-month EBITDA margin and <a href="https://www.investopedia.com/terms/l/levered-free-cash-flow.asp">levered FCF margin</a> of 20.11% and 1.94% are 247.6% and 120.4% higher than the industry averages of 5.79% and 0.88%, respectively.
ELAN's revenue for the fiscal first quarter that ended March 31, 2024, stood at $1.21 billion. Its adjusted EBITDA came in at $294 million. Moreover, its non-GAAP net income stood at $167 million. Also, its non-GAAP earnings per share amounted to $0.34.
Analysts expect ELAN's revenue and EPS for the quarter ending June 30, 2024, to increase 9% and 33.8% year-over-year to $1.15 billion and $0.24, respectively. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 88.9%, closing the last trading session at $17.
ELAN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this promising outlook. It has an overall rating of B, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
ELAN has a B grade for Growth, Value, and Sentiment. It is ranked #40 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. Beyond what we stated above, we have also rated ELAN for Momentum, Stability, and Quality. Get all the ELAN ratings <a href="https://stocknews.com/stock/ELAN/">here</a>.
Stock #2: Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>)
VTRS offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
On April 15, 2024, VTRS announced the launch of PrGlatiramer Acetate Injection 20 mg/mL in Canada, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis, a chronic inflammatory disease of the central nervous system.
On April 1, 2024, VTRS launched RYZUMVI in the U.S. It's the sole FDA-approved eye drop that helps reverse medication-induced dilation, helping in eye exams and spotting eye/systemic issues. It takes effect in around 30 minutes.
VTRS' trailing-12-month EBIT margin of 13.63% is 923.7% higher than the industry average of 1.33%. Its trailing-12-month EBITDA margin and levered FCF margin of 30.81% and 6.64% are 432.5% and 654.5% higher than the industry averages of 5.79% and 0.88%, respectively.
For the fiscal first quarter that ended March 31, 2024, VTRS' total revenues and adjusted gross profit stood at $3.66 billion and $2.15 billion, respectively. Its adjusted EBITDA amounted to $1.19 billion. For the same quarter, its adjusted net earnings and EPS stood at $812.70 million and $0.67, respectively.
Street expects VTRS' EPS for the quarter ending December 31, 2024, to increase 9.7% year-over-year to $0.68. VTRS' stock has gained 21.3% over the past six months, closing the last trading session at $11.16.
VTRS' POWR Ratings reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system.
VTRS has an A grade for Value and a B for Growth. Within the same industry, it is ranked #39. <a href="https://stocknews.com/stock/VTRS/">Click here</a> for the additional POWR Ratings for VTRS (Momentum, Stability, Sentiment, and Quality).
Stock #1: Astellas Pharma Inc. (<a href="https://stocknews.com/stock/ALPMY/">ALPMY</a>)
Headquartered in Tokyo, Japan, ALPMY manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company mainly operates in the Pharmaceutical Products business segment.
On May 1, 2024, ALPMY and Poseida announced a research collaboration to develop novel convertibleCAR programs targeting solid tumors, combining Poseida's allogeneic CAR-T platform with ALPMY's Xyphos ACCELTM technology, aiming to address significant unmet needs in cancer therapy.
On April 23, 2024, ALPMY announced that the European Commission approved a label extension for XTANDI as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy.
ALPMY's trailing-12-month asset turnover ratio of 0.53x is 33.7% higher than the industry average of 0.40x. Similarly, its trailing-12-month gross profit margin and EBITDA margin of 81.76% and 15.26% are 44.5% and 163.7% higher than the industry averages of 56.59% and 5.79%, respectively.
ALPMY's revenue for the fiscal year that ended March 31, 2024, increased 5.6% year-over-year to ¥1.60 trillion ($10.29 billion). The company's gross profit rose 6.6% from the year-ago value to ¥1.31 trillion ($8.42 billion). ALPMY's core profit for the year stood at ¥150.98 billion ($969.04 million) or ¥84.19 per share.
In addition, as of March 31, 2024, ALPMY's total current assets amounted to ¥1.19 trillion ($7.67 billion), compared to ¥1.05 trillion ($6.74 billion) as of March 31, 2023.
For the quarter ending June 30, 2024, ALPMY's revenue is expected to increase 2.1% year-over-year to $2.67 billion. Its EPS for fiscal 2025 is expected to increase 382% year-over-year to $0.30. It surpassed consensus revenue estimates in each of the trailing four quarters. The stock has declined 1.8% intraday to close the last trading session at $9.72.
ALPMY's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of B, equating to Buy in our proprietary rating system.
It has an A grade for Stability and a B for Value. It is ranked #36 in the Medical - Pharmaceuticals industry. To see ALPMY's Growth, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/ALPMY/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ALPMY shares were trading at $9.61 per share on Monday morning, down $0.11 (-1.09%). Year-to-date, ALPMY has declined -19.24%, versus a 10.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Neha Panjwani</h2> <img src='https:/wp-content/uploads/2024/01/Neha-Panjwani_Headshot-1.jpeg' style="float:left; padding:5px;width:125px;">From her school days, Neha harbored a profound fascination for finance, a passion that steered her toward a career as an investment analyst following the completion of her bachelor's degree in commerce. Currently enrolled in the CFA program, Neha is dedicated to further enriching her comprehension of investment fundamentals.

Neha's primary objective is to aid retail investors in discerning optimal investment opportunities by diligently evaluating crucial aspects of financial instruments, with a primary focus on stocks and ETFs. Her commitment lies in empowering individuals to make informed and strategic investment decisions in the dynamic world of finance.<a href="https://stocknews.com/authors/?author=neha-panjwani">More...</a>The post <a href=https://stocknews.com/news/alpmy-vtrs-elan-3-top-rated-pharma-stocks-to-diversify-your-portfolio/>3 Top-Rated Pharma Stocks to Diversify Your Portfolio</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Top-Rated Pharma Stocks to Diversify Your Portfolio

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2024 Update

ALLO

ALPMY

AMAT

AMZN

BLUE

CSCO

DOCS

ELAN

FTRE

GOOG

GOOGL

HCAT

INTC

KVUE

KYTX

MDRX

TCKRF

TECK

UBER

VRTX

WFCNP

Press Releases

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

Contracts

Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health

Viatris to Participate in the BofA Securities 2024 Health Care Conference

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

OCUP

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Viatris Stock (NASDAQ:VTRS), Short Interest Report

People Also Watch